{"filings":[{"id":695360,"accession_number":"0001140361-26-022979","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-05-27T20:01:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA with Priority Review for BBP-418 to treat LGMD2I/R9; PDUFA target action date November 27, 2026.","No advisory committee meeting currently planned for the application.","Phase 3 FORTIFY trial met all primary and secondary endpoints; treated patients improved while placebo declined.","If approved, BBP-418 would be first and only therapy for LGMD2I/R9 and first approved treatment for any form of LGMD.","BridgeBio plans to start studies in patients under 12 years and in LGMD2M/R13 and LGMD2U/R20."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67844,"accession_number":"0001140361-26-021036","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-05-13T20:01:37+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio submits NDA to FDA for encaleret in ADH1; Phase 3 data shows 76% achieved target calcium levels","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted for encaleret, a potential first approved therapy for autosomal dominant hypocalcemia type 1 (ADH1).","Phase 3 CALIBRATE trial met all primary and key secondary endpoints: 76% on encaleret vs 4.4% on standard of care achieved both serum and urine calcium targets at Week 24 (p<0.0001).","BridgeBio anticipates U.S. launch in early 2027; NDA may be eligible for priority review.","Planned MAA submission to EMA in H2 2026; also plans to initiate RECLAIM-HP Phase 3 study in chronic hypoparathyroidism in Summer 2026.","Safety profile favorable: no discontinuations in encaleret arm; low rates of serious adverse events similar between arms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95134,"accession_number":"0001140361-26-019761","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"BridgeBio Pharma establishes $500M at-the-market equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $500M in common stock may be sold via ATM through Goldman Sachs and Leerink Partners.","Sales agents will receive up to 3.0% commission on gross proceeds; company not obligated to sell.","Prior May 2023 equity distribution agreement terminated in conjunction with new facility.","Registration statement on Form S-3ASR filed to support the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95133,"accession_number":"0001743881-26-000018","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.","Net loss attributable to common stockholders $164.0M ($0.84 per share), vs $167.4M ($0.88) in Q1 2025.","Cash, equivalents & marketable securities $940.2M as of March 31, 2026, up from $587.5M at Dec 31.","Board authorized $500M stock repurchase program; buybacks may occur open market or privately.","Submitted NDA for BBP-418 (LGMD2I/R9) to FDA; encaleret NDA planned 1H 2026; infigratinib NDA Q3 2026."],"consensus_eps_estimate":-0.6921,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":194515000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107987,"accession_number":"0001140361-26-011991","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio submits NDA to FDA for BBP-418 for LGMD2I/R9; potential first approved therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submission for oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9.","Phase 3 FORTIFY interim analysis met all primary and secondary endpoints at 12 months.","FDA approval and U.S. launch anticipated in late 2026 / early 2027.","BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease designations from FDA.","Company also engaging European regulators for expedited approval path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107986,"accession_number":"0001743881-26-000008","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).","Attruby (ATTR-CM) net product revenue $146.0M in Q4; 7,804 patient prescriptions as of Feb 20.","Phase 3 FORTIFY (LGMD2I/R9) met endpoints; 2.6-point NSAD improvement vs placebo at 12 months.","Phase 3 PROPEL 3 (infigratinib, achondroplasia) met primary endpoint; mean AHV +2.10 cm/year vs placebo.","Cash $587.5M at Dec 31; completed $632.5M convertible notes Jan 2026."],"consensus_eps_estimate":-0.757,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":502076000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107985,"accession_number":"0001140361-26-004995","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio reports positive Phase 3 infigratinib results in achondroplasia; NDA/MAA planned H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PROPEL 3 met primary endpoint: change from baseline in AHV at Week 52 (p<0.0001); mean treatment difference +2.10 cm/year.","First statistically significant improvement in body proportionality vs placebo in children <8 years (LS mean -0.05, p<0.05).","Key secondary endpoint height Z-score (achondroplasia reference) LS mean increase +0.41 SD on treatment (p<0.0001).","No discontinuations or serious AEs related to study drug; 3 cases (4%) mild transient hyperphosphatemia, no FGFR1/2 AEs.","NDA and MAA submissions for achondroplasia planned in second half of 2026; accelerate hypochondroplasia development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107984,"accession_number":"0001140361-26-001843","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.","Net proceeds ~$619.3M; intended to repurchase, settle, or repay at maturity the 2.50% 2027 notes.","Concurrent $82.5M share repurchase: 1,081,825 shares at $76.26/share from note purchasers.","Initial conversion price ~$110.58/share, a ~45% premium over Jan 15 close of $76.26.","Notes are senior unsecured; redemption permitted after Feb 6, 2030 if stock >=130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107983,"accession_number":"0001140361-26-000971","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.","6,629 unique patient prescriptions for Attruby written by 1,632 prescribers as of Dec 31, 2025, reflecting rapid adoption.","New TTR amyloid depleter antibody program to explore ATTR-CM disease reversal; clinic expected between 2027-2028.","FDA recommends NDA for BBP-418 (LGMD2I/R9) toward full approval after positive FORTIFY interim; submission planned H1 2026.","Encumeret NDA for ADH1 planned H1 2026; Phase 3 RECLAIM-HP in chronic hypoparathyroidism to start summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124394,"accession_number":"0001743881-25-000010","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio Q3 2025: $120.7M revenue, Attruby launch accelerating; positive Phase 3 data for BBP-418 and encaleret","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $120.7M (Q3 2024: $2.7M), driven by $108.1M Attruby net product revenue.","Net loss $182.7M ($0.95/sh) vs $162.0M ($0.86/sh) in prior year; cash $645.9M.","Attruby: 5,259 prescriptions written by 1,355 prescribers since Nov 2024 approval.","BBP-418 Phase 3 met endpoints: glycosylated αDG increased 1.8x (p<0.0001); NDA filing planned 1H 2026.","Encaleret Phase 3 met primary endpoint: 76% achieved target calcium vs 4% on conventional (p<0.0001); NDA in 1H 2026."],"consensus_eps_estimate":-0.9064,"consensus_eps_actual":-2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":347898000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124393,"accession_number":"0001140361-25-039705","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).","91% on encaleret achieved intact PTH above lower limit vs 7% on conventional therapy (p<0.0001).","Encaleret was well-tolerated with no discontinuations related to study drug.","NDA submission to FDA planned H1 2026; EMA submission to follow.","BridgeBio plans to initiate registrational trials in pediatric ADH1 and chronic hypoparathyroidism in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124392,"accession_number":"0001140361-25-039463","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio Phase 3 FORTIFY study hits all primary and secondary endpoints for BBP-418 in LGMD2I/R9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: glycosylated αDG increased 1.8x from baseline at 3 months (p<0.0001); sustained at 12 months.","Serum CK (muscle damage marker) reduced by 82% from baseline vs placebo at 12 months (p<0.0001).","100-meter walk test velocity improved 0.27 m/s vs placebo at 12 months (p<0.0001).","FVC pulmonary function improved ~5% predicted volume vs placebo at 12 months (p=0.0071).","Company plans to file NDA with FDA in first half 2026; safety profile consistent with prior studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141065,"accession_number":"0000950170-25-102985","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio Q2 2025 rev $110.6M, Attruby sales $71.5M, net loss $181.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $110.6M vs $2.2M prior year; Attruby net product revenue $71.5M.","Net loss attributable to common stockholders $181.9M ($0.95 EPS) vs $73.5M ($0.39 EPS) prior year.","As of Aug 1, 2025, 3,751 unique patient prescriptions for Attruby by 1,074 prescribers; launch accelerating.","Pipeline: FORTIFY (LGMD2I/R9) and CALIBRATE (ADH1) topline results expected fall 2025; PROPEL 3 (achondroplasia) early 2026.","Cash, cash equivalents and marketable securities $756.9M; raised $300M via royalty sale."],"consensus_eps_estimate":-0.8602,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":227198000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141064,"accession_number":"0001140361-25-024413","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.","Purchase price of $300M paid in full at closing on June 27, 2025.","Purchaser's annual cap equals 60% of Bayer royalties on first $500M of net sales; hard cap at 145% of purchase price.","Company granted security interest in assets related to purchased royalty payment; change of control triggers option to assume or pay adjusted amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158866,"accession_number":"0001140361-25-023362","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"BridgeBio stockholders approve officer exculpation amendment and 5M-share increase in stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all five Class III director nominees: Kumar, Homcy, Dachille, Daniels, Lo.","Approved amendment to increase shares reserved under 2021 Stock Plan by 5,000,000 shares (128.9M for, 26.7M against).","Approved officer exculpation amendment to limit liability of certain officers as permitted under Delaware law (151.2M for, 5.6M against).","Ratified Deloitte & Touche as independent auditor for FY2025 (173.8M for, 56k against).","Non-binding advisory vote on executive compensation passed (117.6M for, 37.9M against, 1.2M abstain)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158865,"accession_number":"0000950170-25-060085","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.","Net loss attributable to common stockholders $167.4M ($0.88 EPS) vs $35.2M ($0.20) YoY; total revenue $116.6M vs $211.1M.","Cash $540.6M at March 31, 2025; expects $105M milestone payments in Q2 for ex-U.S. BEYONTTRA approvals.","Phase 2 encaleret in hypoparathyroidism: 78% of 9 patients achieved normal blood & urine calcium within 5 days.","Priced $500M 1.75% convertible notes due 2031; used $459M to repay term loan; Thomas Trimarchi appointed President/CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":116633000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177260,"accession_number":"0001140361-25-009063","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BridgeBio Pharma appoints Thomas Trimarchi as President and CFO; former CFO departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Stephenson's employment ended March 17, 2025; receives 9 months base salary and COBRA.","Stephenson to serve as consultant from March 17, 2025 through March 17, 2026.","Thomas Trimarchi appointed President and CFO; effective immediately.","Stephenson's departure is for personal reasons and not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177259,"accession_number":"0001140361-25-006524","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"BridgeBio closes $575M 1.75% convertible notes due 2031; refinances Blue Owl secured debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $575M aggregate principal of 1.75% convertible senior notes due March 1, 2031.","Net proceeds of ~$563M; used $48.3M to repurchase 1.4M shares at $34.35.","Repaid and terminated Financing Agreement with Blue Owl, eliminating ~$51.5M annual interest.","Notes are senior unsecured; conversion price ~$49.81 per share (45% premium).","May not redeem before March 6, 2028; can redeem after if stock exceeds 130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177258,"accession_number":"0000950170-25-023741","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio reports Q4 net loss of $1.40/share; Attruby launch with 1,028 scripts, EU approval triggers $75M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.","Q4 2024 net loss $265.1M ($1.40 EPS); full-year net loss $535.8M ($2.88 EPS).","Q4 revenue $5.9M including $2.9M Attruby sales; full-year revenue $221.9M driven by $207.7M from Bayer/Kyowa Kirin deals.","Cash, cash equivalents and short-term restricted cash $681.2M at Dec 31, 2024, up from $392.6M at Dec 31, 2023.","Three Phase 3 trials (LGMD2I, ADH1, achondroplasia) fully enrolled; last participant last visit expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":221902000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177257,"accession_number":"0001140361-25-000943","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BridgeBio reports early Attruby demand: 430 scripts from 248 physicians; three Phase 3 trials fully enrolled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.","Three Phase 3 trials fully enrolled: FORTIFY (LGMD2I/R9, n=112), CALIBRATE (ADH1, n=70), PROPEL 3 (achondroplasia, n=114).","Cash $406M last quarter; received $500M upon acoramidis FDA approval from royalty facility; expects $105M milestones in 1H 2025.","Milestones: EU/Japan acoramidis approvals in 1H 2025; topline readouts FORTIFY & CALIBRATE in 2H 2025; PROPEL 3 LPLV in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194026,"accession_number":"0001140361-24-047704","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).","Phase 3 ATTRibute-CM: 42% reduction in composite ACM and recurrent CVH at Month 30; 50% reduction in cumulative CVH events.","BridgeBio to receive $500M payment under royalty funding agreement upon approval.","List price: $18,759.12 for 28-day supply; free for life for U.S. trial participants.","MAA submitted to EMA; decision expected in 2025; Bayer has exclusive EU commercialization rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194025,"accession_number":"0000950170-24-124576","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.","Cash, equivalents, and short-term restricted cash $405.7M; expects $500M milestone from acoramidis upon FDA approval.","FDA accepted acoramidis NDA; PDUFA date November 29, 2024; 42-month OLE data to be presented at AHA.","FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia.","Phase 3 FORTIFY trial for LGMD2I/R9 enrollment completed; interim analysis expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":216020000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210363,"accession_number":"0001140361-24-040755","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio halts CAH gene therapy after Phase 1/2 shows cortisol production but not transformative; cuts budget $50M+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 ADventure trial of BBP-631 in classic CAH: increased endogenous cortisol in all higher-dose patients (max change 6.6 µg/dL post-ACTH); well tolerated with no treatment-related SAEs.","BBP-631 achieved durable transgene activity: 55-fold avg increase in 11-deoxycortisol at highest doses; ≥50% reduction in 17-OHP in majority of patients.","Company discontinues BBP-631 development for CAH, citing data not meeting threshold for additional capital investment; budget cut >$50M.","BridgeBio seeking partnership opportunities for BBP-631 or next-gen CAH gene therapies; est. >75,000 CAH cases in US+EU.","CFO states reserving gene therapy for priority targets like Canavan disease; will work with FDA to accelerate Canavan therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210362,"accession_number":"0001140361-24-037974","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.","Investors including Viking Global, Patient Square, Sequoia, Frazier, Cormorant, and Aisling committed $300M in tranches.","CEO Neil Kumar's entity also invested; BridgeBio's initial interest ~45%, subject to dilution.","Special committee of independent directors approved with Goldman Sachs as financial advisor.","JV will research, develop, manufacture and commercialize the contributed programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210361,"accession_number":"0000950170-24-088952","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.","Acoramidis NDA for ATTR-CM accepted; PDUFA date Nov 29, 2024; 42% reduction in composite CVH and ACM events at Month 30.","Cash, equivalents, marketable securities and short-term restricted cash $587.2M as of June 30, up from $392.6M at Dec 31, 2023.","Phase 3 FORTIFY study (BBP-418 for LGMD2I/R9) surpassed interim analysis enrollment target; top-line data expected 2025.","Infigratinib in achondroplasia: +2.50 cm/yr annualized height velocity at Month 18 (p=0.0015), significant body proportionality improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":213288000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210360,"accession_number":"0001140361-24-033856","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BridgeBio appoints Thomas Trimarchi as President and COO; Neil Kumar remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Trimarchi appointed President and COO effective July 23, 2024; Neil Kumar steps down as President but stays CEO and director.","Trimarchi previously served as Chief Product Officer since 2018; also board member of affiliate ML Bio Solutions (BBP-418 for LGMD2I/R9).","Newly created role to drive operational excellence, strategic planning, and centralize late-stage pipeline operations.","Trimarchi holds a Ph.D. in Molecular Oncology and Immunology from NYU; prior roles at Regeneron and Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228674,"accession_number":"0001140361-24-031087","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BridgeBio shareholders approve all proposals, including 6.5M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Eric Aguiar, Jennifer Cook, Andrea Ellis, Fred Hassan, Ali Satvat.","Advisory say-on-pay vote passed with ~134.3M for, ~9.3M against.","Deloitte & Touche ratified as independent auditor for fiscal 2024.","2021 Stock Plan amended to increase shares reserved by 6.5 million.","Broker non-votes were 17.3M on director election and most other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228673,"accession_number":"0001140361-24-029050","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BridgeBio reports positive Phase 2 infigratinib results in achondroplasia; initiates hypochondroplasia study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).","Statistically significant improvement in body proportionality: upper/lower segment ratio 1.88 at Month 18 vs 2.02 baseline (p=0.001).","No treatment-related adverse events in Cohort 5; drug well-tolerated as single daily oral therapy.","First child consented in ACCEL observational study for hypochondroplasia; Phase 2/3 interventional study planned.","PROPEL 3 Phase 3 registrational enrollment on schedule, completion estimated by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228672,"accession_number":"0000950170-24-051573","cik":1743881,"company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.","Launched BBOT oncology subsidiary with $200M private financing led by Cormorant and Omega.","Secured up to $1.5B via Bayer licensing (up to $310M milestones), royalty financing, and equity.","Acoramidis NDA PDUFA date Nov 29, 2024; EMA MAA accepted, expected approval 2025.","Ended Q1 with $519.8M cash; cash position strengthened significantly."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":211120000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13181461705.64118,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}